Post by mannmade on Jun 28, 2018 20:09:45 GMT -5
seekingalpha.com/news/3367072-liquidia-technologies-files-57_5m-ipo#email_link
Liquidia Technologies files for $57.5M IPO
Jun. 28, 2018 9:03 PM ET|By: Jason Aycock, SA News Editor
Biopharmaceutical firm Liquidia Technologies has filed for an initial public offering.
It's looking for up to $57.5M, via Jefferies and Cowen.
The company's looking to list on Nasdaq Capital Market under the symbol LQDA.
For the three months ended March 31, revenues were $925,970 vs. a year-ago $1.639M. Operating loss swelled to $8.88M from $6.77M, and net loss was $27.5M vs. a year-ago $9.84M.
Potential competitors, particularly considering the area of pulmonary arterial hypertension, include Insmed (NASDAQ:INSM), MannKind (NASDAQ:MNKD), Durect (NASDAQ:DRRX), Innocoll, Heron Therapeutics (NASDAQ:HRTX), United Therapeutics (NASDAQ:UTHR), and Actelion (OTCPK:ALIOY)
Liquidia Technologies files for $57.5M IPO
Jun. 28, 2018 9:03 PM ET|By: Jason Aycock, SA News Editor
Biopharmaceutical firm Liquidia Technologies has filed for an initial public offering.
It's looking for up to $57.5M, via Jefferies and Cowen.
The company's looking to list on Nasdaq Capital Market under the symbol LQDA.
For the three months ended March 31, revenues were $925,970 vs. a year-ago $1.639M. Operating loss swelled to $8.88M from $6.77M, and net loss was $27.5M vs. a year-ago $9.84M.
Potential competitors, particularly considering the area of pulmonary arterial hypertension, include Insmed (NASDAQ:INSM), MannKind (NASDAQ:MNKD), Durect (NASDAQ:DRRX), Innocoll, Heron Therapeutics (NASDAQ:HRTX), United Therapeutics (NASDAQ:UTHR), and Actelion (OTCPK:ALIOY)
